NEW YORK (GenomeWeb) – Ideally, molecularly informed drug development is supposed to provide pharmaceutical companies with more confidence about how well their therapies work in a specific patient population. But the recent failure of Bristol-Myers Squibb's immunotherapy Opdivo (nivolumab) to meet its primary endpoint in a late-stage non-small cell lung cancer trial highlights the pitfalls drugmakers face amid evolving science and imperfect biomarkers.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.